Cargando…

DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer

The majority of patients develop resistance against suppression of HER2-signaling mediated by trastuzumab in HER2 positive breast cancer (BC). HER2 overexpression activates multiple signaling pathways, including the mitogen-activated protein kinase (MAPK) cascade. MAPK phosphatases (MKPs) are essent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menyhart, Otília, Budczies, Jan, Munkácsy, Gyöngyi, Esteva, Francisco J., Szabó, András, Miquel, Teresa Puig, Győrffy, Balázs
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652774/ https://www.ncbi.nlm.nih.gov/pubmed/29100381 http://dx.doi.org/10.18632/oncotarget.20430

Ejemplares similares

Independent validation of induced overexpression efficiency across 242 experiments shows a success rate of 39%
por: Munkácsy, Gyöngyi, et al.
Publicado: (2019)

Pancancer survival analysis of cancer hallmark genes
por: Nagy, Ádám, et al.
Publicado: (2021)

Gene Expression Profiling in Early Breast Cancer—Patient Stratification Based on Molecular and Tumor Microenvironment Features
por: Munkácsy, Gyöngyi, et al.
Publicado: (2022)

Comparison of scientometric achievements at PhD and scientific output ten years later for 4,790 academic researchers
por: Munkácsy, Gyöngyi, et al.
Publicado: (2022)

Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Munkácsy, Gyöngyi, et al.
Publicado: (2023)

Demographic shift disproportionately increases cancer burden in an aging nation: current and expected incidence and mortality in Hungary up to 2030
por: Menyhárt, Otília, et al.
Publicado: (2018)

TP53 mutation hits energy metabolism and increases glycolysis in breast cancer
por: Harami-Papp, Hajnalka, et al.
Publicado: (2016)

Author Correction: Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets
por: Nagy, Ádám, et al.
Publicado: (2018)

Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets
por: Nagy, Ádám, et al.
Publicado: (2018)

Principles of tumorigenesis and emerging molecular drivers of SHH‐activated medulloblastomas
por: Menyhárt, Otília, et al.
Publicado: (2019)

Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches
por: Menyhárt, Otília, et al.
Publicado: (2020)

Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis
por: Menyhárt, Otília, et al.
Publicado: (2021)

Currently favored sampling practices for tumor sequencing can produce optimal results in the clinical setting
por: Pongor, Lőrinc S., et al.
Publicado: (2020)

Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas
por: Menyhárt, Otília, et al.
Publicado: (2019)

Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma
por: Menyhárt, Otília, et al.
Publicado: (2018)

MultipleTesting.com: A tool for life science researchers for multiple hypothesis testing correction
por: Menyhart, Otília, et al.
Publicado: (2021)

Correction: MultipleTesting.com: A tool for life science researchers for multiple hypothesis testing correction
por: Menyhart, Otília, et al.
Publicado: (2022)

Proteotranscriptomic Discrimination of Tumor and Normal Tissues in Renal Cell Carcinoma
por: Bartha, Áron, et al.
Publicado: (2023)

Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer
por: Menyhárt, Otília, et al.
Publicado: (2019)

Gene Expression Indicates Altered Immune Modulation and Signaling Pathway Activation in Ovarian Cancer Patients Resistant to Topotecan
por: Menyhárt, Otília, et al.
Publicado: (2019)

Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies
por: Menyhárt, Otília, et al.
Publicado: (2021)

Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
por: Győrffy, Balázs, et al.
Publicado: (2013)

The prognostic association of SPAG5 gene expression in breast cancer patients with systematic therapy
por: Zhu, Chenjing, et al.
Publicado: (2019)

Validation of RNAi Silencing Efficiency Using Gene Array Data shows 18.5% Failure Rate across 429 Independent Experiments
por: Munkácsy, Gyöngyi, et al.
Publicado: (2016)

An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes
por: Győrffy, Balázs, et al.
Publicado: (2018)

Uncovering Potential Therapeutic Targets in Colorectal Cancer by Deciphering Mutational Status and Expression of Druggable Oncogenes
por: Menyhart, Otília, et al.
Publicado: (2019)

New network topology approaches reveal differential correlation patterns in breast cancer
por: Bockmayr, Michael, et al.
Publicado: (2013)

Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types
por: Budczies, Jan, et al.
Publicado: (2017)

Kinetic Modeling of DUSP Regulation in Herceptin-Resistant HER2-Positive Breast Cancer
por: Buiga, Petronela, et al.
Publicado: (2019)

DUSP5 and DUSP6 modulate corneal epithelial cell proliferation
por: Wang, Zheng, et al.
Publicado: (2010)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Elevated HOX gene expression in acute myeloid leukemia is associated with NPM1 mutations and poor survival
por: Nagy, Ádám, et al.
Publicado: (2019)

KRAS driven expression signature has prognostic power superior to mutation status in non‐small cell lung cancer
por: Nagy, Ádám, et al.
Publicado: (2016)

DUSPs, to MAP kinases and beyond
por: Huang, Ching-Yu, et al.
Publicado: (2012)

Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization
por: Budczies, Jan, et al.
Publicado: (2012)

Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation
por: Lánczky, András, et al.
Publicado: (2021)

A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients
por: Pongor, Lőrinc, et al.
Publicado: (2015)

Molecular mechanisms of resistance to HER2-targeted therapy
por: Esteva, FJ
Publicado: (2009)

The cytotoxic action of BCI is not dependent on its stated DUSP1 or DUSP6 targets in neuroblastoma cells
por: Thompson, Elliott M., et al.
Publicado: (2022)

RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer
por: Sanz-Moreno, Adrián, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5h9mimea4seso4tmr1qgtontuo